Amplified Sciences, a clinical-stage diagnostics company pioneering next-generation multi-omic assays, today announced new investment from the American Gastroenterology Association’s (AGA) GI Opportunities Fund as part of its recent Seed+ funding round. The round was led by existing investor OCA Ventures, with additional institutional investors participating.
This investment reflects growing confidence from leading gastroenterology stakeholders in PanCystPro, Amplified Sciences’ first diagnostic assay designed to improve risk stratification of pancreatic cystic lesions and support more accurate clinical decision-making.
With the widespread use of high-resolution imaging, pancreatic cysts are increasingly being detected in clinical practice, and prevalence estimates have increased significantly over the past two decades. Although many cysts are benign, some carry the risk of malignant transformation into pancreatic ductal adenocarcinoma, one of the deadliest cancers. Current diagnostic approaches often lack the precision necessary to confidently guide management, leading to unnecessary surgery and prolonged surveillance.
The investment from AGA’s GI Opportunity Fund is a strong indicator of the clinical need for better tools in pancreatic cyst management. PancystPro is designed to help clinicians more accurately distinguish between high-risk cysts and benign lesions, enabling more confident, evidence-based decision-making. ”
Diana Caldwell, CEO of Amplified Sciences
“The Gastrointestinal Opportunities Fund invests in innovations that can meaningfully improve patient outcomes and clinical effectiveness,” said AGA President Dr. Byron Cryer. “Amplified Sciences’ approach to pancreatic cyst diagnosis represents a promising advance in the challenging field of gastroenterology.”
“As the detection of pancreatic cysts continues to increase, the demand for accurate, low sample volume diagnosis is becoming increasingly urgent. PanCystPro aims to positively impact how clinicians evaluate these patients and ultimately improve outcomes.”
Proceeds from the financing will support the completion of pivotal real-world observational studies to demonstrate clinical utility, expand commercial partnerships, validate additional tests in the company’s CLIA-CAP certified laboratory, and expand market access for PanCystPro.
sauce:
American College of Gastroenterology
